Compare Gilead Sciences, Inc. (GILD) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs HP Inc — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while HP Inc trades at $23.96 (market cap $21.72B). The key difference: Gilead Sciences, Inc. is far larger — about 7.5× HP Inc's market cap, and HP Inc pays the higher dividend (5.05%). Which is the better fit depends on your goals.
| GILD | HPQ | |
|---|---|---|
Market Cap | $163.51B | $21.72B |
Sector | Health | Technology |
52-Week High | $155.80 | $29.35 |
52-Week Low | $108.22 | $18.20 |
Enterprise Value | $178.05B | $28.88B |
Dividend Yield | 2.49% | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
HPQ trades at $23.71, down 3.74% over 24 hours, with a bullish technical signal from moving averages and ADX indicators. Fundamentally, the stock shows value with a P/E of 8.8 and P/S of 0.39, supported by three consecutive quarterly EPS beats. Recent developments include a strategic partnership with OpenAI and a dividend yield near 5%, while cash flow trends improved to a net $460 million in 2025.
The outlook balances undervaluation and dividend appeal against PC market headwinds and negative equity. Risks include industry shipment declines and competitive pressure, but analyst consensus leans hold with a $22 price target, suggesting cautious optimism for AI-driven growth opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
